MRTX Mirati Therapeutics Options Ahead of EarningsAnalyzing the options chain and the chart patterns of MRTX Mirati Therapeutics prior to the earnings report this week,
I would consider purchasing the 35usd strike price Puts with
an expiration date of 2023-9-15,
for a premium of approximately $0.57.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
Mirati
Mirati Therapeutics (NASDAQ: $MRTX) Flashes Signs Of Reversal 🚦Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Mirati Therapeutics good news. The price will start to rise soonI spent about 3 hours researching this company and I will divide my work into 3 parts. Last report, other positive news, and why you shouldn't open long position right now. Enjoy reading.
1) Mirati Therapeutics Reports First Quarter 2021 Financial Results (May 06, 2021)
The most important information:
- Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - POSITIVE NEWS
- Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - POSITIVE NEWS
- Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor - POSITIVE NEWS
- Research and development expenses for the first quarter of 2021 were $104.1 million, compared to $71.7 million for the same period in 2020. !!!!!!!!!! - IMPORTANT
2) Other positive news (Jun 01, 2021)
- Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
- Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties
3) Why you shouldn't open long position right now
First, there are too many resistance lines at the moment. I doubt that the price will suddenly rise now and break through all resistance lines.
After the May report, the price did not break the white resistance line. Most likely, the next report will raise the price and in my opinion, there is a good chance that it will end the bear market this year.
